Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Tomivosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 03 Aug 2018 Status changed from planning to recruiting.
- 18 Apr 2018 New trial record
- 16 Apr 2018 According to an Effector Therapeutics media release, this study is expected to be initiated by the end of 2018.